Rohit Loomba, MD, Named Chief of the Division of Gastroenterology and Hepatology
June 13, 2023
Loomba will lead the division at UC San Diego School of Medicine, building upon a team that shines a light on UC San Diego Health’s tripartite mission.
Your search for “Gastroenterology and Digestive Health” returned 27 results
Novel Cytokine Protects Mice from Colitis
August 24, 2011
Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.
U.S. News & World Report: UC San Diego #1 for Gastroenterology and Hepatology Research
October 28, 2020
U.S. News & World Report named University of California San Diego School of Medicine a top global university and ranked the divisions of Gastroenterology and Hepatology #1 in the world for research.
Modest Alcohol Use Lowers Risk and Severity of Some Liver Disease
April 19, 2012
People with nonalcoholic fatty liver disease (NALFD) who consume alcohol in modest amounts – no more than one or two servings per day – are half as likely to develop hepatitis as non-drinkers with the same condition, reports a national team of scientists led by researchers at the University of…
Pediatric Liver Disease Increases Risk of Developing Type 2 Diabetes
June 13, 2022
UC San Diego researchers describe connection between pediatric liver disease and increased risk of developing type 2 diabetes. Both rates are rising in children.
Two Studies Identify Potential New Drug for Crohn’s Disease and Ulcerative Colitis
August 21, 2013
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn’s disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of…
Gastrointestinal Hormone Measurably Improved Symptoms of Non-Alcoholic Fatty Liver Disease
March 8, 2018
Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and…
UC San Diego Launches New Nonalcoholic Fatty Liver Disease Research Center
February 8, 2016
Roughly one-quarter of all Americans – an estimated 100 million adults and children – have nonalcoholic fatty liver disease (NAFLD), a chronic condition that can lead to cirrhosis, liver cancer and liver failure. Combining a diverse array of basic science, biomarkers, imaging and clinical efforts, University of California, San Diego…
Study: Potential New Treatment Identified for Liver Disease
June 26, 2023
Researchers with UC San Diego School of Medicine identified a potential new drug that improved liver fibrosis in patients with NASH by 27%.
New Clinic Provides Comprehensive Care for Digestive Diseases in Westfield UTC
April 18, 2022
UC San Diego Health announces the opening of a new, multi-disciplinary clinic for patients with gastrointestinal and digestive diseases. The state-of-the-art clinic is the first of its kind in San Diego County to offer the most advanced care by a wide range of specialists under one roof.
